Skip to main content

Advertisement

Table 1 Clinical characteristics of the patients with NAFLD and control subjects

From: Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease

  NAFLD (n = 253) Control (n = 578) Pvalue
Men/women 122/131 182/396 <0.0001*
Age (year) 51.7 ± 15.0 (38.0; 52.5; 64.0) 47.2 ± 14.8 (34.0; 49.0; 57.0) <0.0001
BMI (kg/m2) 27.7 ± 5.3 (24.4; 27.3; 29.8) 21.3 ± 2.2 (19.8; 21.4; 23.1) <0.0001
FBS (mg/dL) 117.1 ± 34.6 (99.0; 108.0; 124.0) 90.9 ± 7.7 (85.0; 90.5; 96.0) <0.0001
HbA1c (%) 5.9 ± 1.2 (5.1; 5.5; 6.3) 5.0 ± 0.4 (4.8; 5.0; 5.3) <0.0001
Total cholesterol (mg/dL) 212.3 ± 37.9 (183.0; 212.0; 237.0) 202.3 ± 34.4 (177.0; 202.0; 223.0) 0.0014
Triglycerides (mg/dL) 169.9 ± 97.7 (112.0; 148.0; 205.0) 75.7 ± 28.6 (53.0; 70.0; 95.0) <0.0001
HDL cholesterol (mg/dL) 52.5 ± 17.4 (42.0; 49.0; 58.0) 67.4 ± 14.0 (57.0; 66.0; 75.8) <0.0001
Systolic blood pressure (mm Hg) 126.7 ± 15.5 (114.0; 125.0; 138.0) 111.1 ± 10.2 (104.0; 112.0; 120.0) <0.0001
Diastolic blood pressure (mm Hg) 77.5 ± 11.4 (70.0; 78.0; 86.0) 69.4 ± 7.5 (64.0; 70.0; 75.8) <0.0001
AST (IU/L) 48.6 ± 29.7 (27.0; 37.0; 64.0) 19.9 ± 6.4 (15.0; 18.0; 23.0) <0.0001
ALT (IU/L) 76.2 ± 50.7 (37.8; 61.0; 93.3) 15.6 ± 6.4 (11.0; 14.0; 19.0) <0.0001
  1. Data are represented as the mean ± SD (25th, 50th, and 75th percentile). P values were obtained by comparing the quantitative phenotype between 2 groups (Mann-Whitney U test). *Men/women ratio was analyzed by Fisher's exact test. AST, aspartate transaminase; ALT, alanine transaminase; BMI, body mass index; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; NAFLD, nonalcoholic fatty liver disease.